Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPG | P10696 | 2/20 | 0.45 |
| ▸ | CDC25A | P30304 | 1/20 | 0.45 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL500712 | 0.86 | ADRB2 (0.40) | ALPGCDC25ACDC25BMEN1KMT2A | |
| SCHEMBL3415445 | 0.85 | CYP3A4 (0.44) | ALPGCDC25ACDC25BMEN1KMT2A | |
| SCHEMBL501275 | 0.85 | ALPG (0.44) | ALPGCDC25ACDC25BMEN1KMT2A | |
| SCHEMBL500776 | 0.85 | ALPG (0.40) | ALPGCDC25ACDC25BMEN1KMT2A | |
| SCHEMBL501169 | 0.84 | HSP90AA1 (0.42) | ALPGCDC25ACDC25BMEN1KMT2A | |
| SCHEMBL501144 | 0.83 | ESR1 (0.42) | ALPGMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL500412 | 0.82 | HSP90AA1 (0.50) | — | |
| SCHEMBL1924364 | 0.82 | MAPT (0.45) | ALPGCDC25ACDC25BALDH1A1LMNA | |
| SCHEMBL501641 | 0.82 | L3MBTL1 (0.47) | ALPGCDC25ACDC25BMEN1KMT2A | |
| SCHEMBL500767 | 0.81 | HSP90AA1 (0.46) | ALPGCDC25ACDC25BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937094-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-20 | — | — | US | claimed |
| US-20130303493-A1 | Triazole Compounds that Modulate HSP90 Activity | SYNTA PHARMACEUTICALS CORP. (US) | 2013-11-14 | — | — | US | claimed |
| EP-2323737-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corp. (US) | 2011-05-25 | — | — | EP | claimed |
| WO-2010017545-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARAMCEUTICALS CORP. (US) | 2010-02-11 | — | — | WO | claimed |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2023-01-03 | — | — | US | disclosed |
| CN-106659765-B | Use of dianhydrogalactitol and analogs or derivatives thereof for treating non-small cell lung cancer and ovarian cancer | 德玛医药 | 2021-08-13 | — | — | CN | disclosed |
| EP-3125920-B1 | DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL OR DIBROMODULCITOL TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2020-12-23 | — | — | EP | disclosed |
| US-20190269646-A9 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2019-09-05 | — | — | US | disclosed |
| US-20180140571-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | BACHA JEFFREY (CA) | 2018-05-24 | — | — | US | disclosed |
| EP-3294284-A1 | COMBINATION OF ANALOGS OR DERIVATIVES OF DIANHYDROGALACTITOL WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT CANCER | Delmar Pharmaceuticals, Inc. (CA) | 2018-03-21 | — | — | EP | disclosed |
| EP-3125920-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | Del Mar Pharmaceuticals (CA) | 2017-02-08 | — | — | EP | disclosed |
| US-9539243-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2017-01-10 | — | — | US | disclosed |
| US-8106083-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106083-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2323737-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corp. (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100113447-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2010-05-06 | — | — | US | disclosed |
| US-20100113447-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2010-05-06 | — | — | US | disclosed |
| US-20100113447-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2010-05-06 | — | — | US | disclosed |
| WO-2010017545-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARAMCEUTICALS CORP. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010017545-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARAMCEUTICALS CORP. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190269646-A9 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DNMT1, MGMT, DCK | ALPG 116/4885CDC25A 47/4885CDC25B 141/4885 |
| US-20100113447-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | ALPG 4245/4885CDC25A 282/4885CDC25B 331/4885 |
| US-20180140571-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DNMT1, MGMT, DCK | ALPG 116/4885CDC25A 47/4885CDC25B 141/4885 |
| US-20130303493-A1 | Triazole Compounds that Modulate HSP90 Activity | HSP90AB1, HSP90B1, HSP90AA1 | ALPG 4245/4885CDC25A 282/4885CDC25B 331/4885 |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DNMT1, MGMT, DCK | ALPG 116/4885CDC25A 47/4885CDC25B 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.